New Drug UDP-003 Shows First Evidence of Removing Toxic Cholesterol Linked to Heart Disease
Cyclarity Therapeutics reveals clinical data showing UDP-003 can safely excrete 7-ketocholesterol, a root driver of arterial plaque, from the human body.
Summary
Cyclarity Therapeutics has shared early clinical trial results showing that its experimental drug UDP-003 can bind to and remove 7-ketocholesterol (7KC) — a toxic oxidized cholesterol compound considered a root cause of arterial plaque buildup — through urinary excretion. The trial, conducted at Monash Victorian Heart Institute, marks the first time this mechanism has been demonstrated safely in humans. Unlike statins and other cardiovascular drugs that work systemically, UDP-003 uses engineered cyclodextrin molecules to precisely target and encapsulate 7KC locally within plaque. This approach aims not just to slow atherosclerosis but to actively reverse it. Researchers note even a 1% reduction in coronary plaque burden may cut major cardiovascular event risk by up to 25%.
Detailed Summary
Cardiovascular disease is the leading cause of death worldwide, yet most treatments manage symptoms rather than address the underlying damage inside arterial walls. A new clinical milestone from Cyclarity Therapeutics may change that trajectory by targeting the root biochemical driver of plaque formation directly.
The company presented early data from a clinical trial at the American Heart Association Vascular Discovery Scientific Sessions, conducted at Australia's Monash Victorian Heart Institute. The results provide the first human evidence that 7-ketocholesterol (7KC) — an oxidized cholesterol byproduct that drives inflammation, cell death, and plaque instability — can be safely bound and excreted from the body via urine.
UDP-003 works through engineered cyclodextrin molecules that act like molecular cages, precisely attracting and encapsulating 7KC. Because cyclodextrins render hydrophobic molecules water-soluble, the trapped 7KC can be flushed out through the kidneys. This local-action mechanism reduces the risk of systemic side effects seen with broader cardiovascular drugs like statins or RNA-based therapies. Researchers describe the effect as analogous to removing rust from metal rather than coating over it.
Beyond heart disease, 7KC is implicated in Alzheimer's disease, non-alcoholic steatohepatitis (NASH), and other age-related conditions, giving this platform broader longevity relevance. Even modest plaque reduction carries outsized benefits: research cited in the release suggests a 1% decrease in coronary plaque burden correlates with up to 25% lower risk of heart attack or stroke.
This is early-stage data, and no efficacy endpoints such as confirmed plaque regression have been reported yet. The trial demonstrates safety and proof-of-concept excretion, not clinical outcomes. Independent peer-reviewed publication and larger randomized trials are needed before UDP-003 can be considered a validated therapy. Still, the mechanism represents a genuinely novel approach to one of longevity medicine's most critical unsolved problems.
Key Findings
- UDP-003 is the first drug to demonstrate safe urinary excretion of 7-ketocholesterol in human clinical trials.
- 7KC drives arterial plaque, inflammation, and cell death and is also implicated in Alzheimer's disease and NASH.
- Even a 1% reduction in coronary plaque burden may lower major cardiovascular event risk by up to 25%.
- Engineered cyclodextrins target 7KC locally within plaque, potentially reducing systemic side effects vs. statins.
- UDP-003 was discovered using an AI-driven drug discovery platform designed to engineer cyclodextrin molecules.
Methodology
This is a press release-based news report published by Lifespan.io summarizing early clinical trial data presented at the American Heart Association Vascular Discovery Scientific Sessions. The source is a reputable longevity-focused outlet, but the underlying data has not yet been published in a peer-reviewed journal. Evidence basis is preliminary clinical proof-of-concept, not a completed efficacy trial.
Study Limitations
Full trial data and peer-reviewed publication are not yet available, limiting independent verification of findings. Safety and excretion data do not confirm plaque reversal or reduced cardiovascular events — those outcomes remain to be studied. The article is based on a company press release, which may emphasize favorable results.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.